// App-Quantinova.ai

3203 : Panobinostat in Combination with Bortezomib and Dexamethasone for Heavily Pre-Treated Myeloma: A UK Real-World Multi-Centre Cohort

Researchers

Presenter

  • Nadjoua Maouche

Principal Investigators

  • Bhuvan Kishore

  • Bhatti Zara

  • Supratik Basu

  • Farheen Karim

  • Sharadha Sundararaman

  • Freya Collings

  • Tseu Bing

  • Heather Leary

  • Noel Ryman

  • Udaya Reddy

  • Grant Vallance

  • Jaimal Kothari

  • Faouzi Djebbari

  • Karthik Ramasamy

Medical Centers

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • The Royal Wolverhampton NHS Trust,Wolverhampton, UK

  • Anaesthesia, Great Western Hospitals NHS FoundationTrust, Swindon, United Kingdom

  • Buckinghamshire Healthcare NHS Trust, Bucks, United Kingdom

  • Hampshire Hospitals Foundation Trust, Winchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Peripheral neuropathy

  • Thrombocytopenia

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Panobinostat

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved